Alnylam Pharmaceuticals, Inc. Earnings

Alnylam Pharmaceuticals, Inc.’s revenue jumped 84.95% since last year same period to $1097.03Mn in the Q4 2025. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated -12.17% fall in its revenue since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit jumped 322.56% since last year same period to $186.42Mn in the Q4 2025. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated -25.75% fall in its net profits since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit margin jumped 220.34% since last year same period to 16.99% in the Q4 2025. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated -15.47% fall in its net profit margins since last 3-months.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.24 - a -13.89% fall from last quarter’s estimates.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 1.24.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) jumped 1983.33% since last year same period to 1.25 in the Q4 2025. This indicates that the Alnylam Pharmaceuticals, Inc. has generated 1983.33% annual rate of jump in its earning per share (EPS) in the last 4 quarters.